These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 14763948)

  • 21. Disappearance of anti-PF4/heparin antibodies under prolonged fondaparinux administration in a patient with DVT associated with LMWH-induced thrombocytopenia.
    D'Angelo A; Valle PD; Fattorini A; Luciano C
    Thromb Haemost; 2006 Mar; 95(3):573-5. PubMed ID: 16525590
    [No Abstract]   [Full Text] [Related]  

  • 22. Tolerance to the synthetic pentasaccharide fondaparinux in heparin sensitization.
    Sacher C; Hunzelmann N
    Allergy; 2003 Dec; 58(12):1318-9. PubMed ID: 14616114
    [No Abstract]   [Full Text] [Related]  

  • 23. Fondaparinux in heparin-induced thrombocytopenia.
    Gevaert A; Smets H; Vercauteren R
    Acta Cardiol; 2013 Oct; 68(5):517-20. PubMed ID: 24283115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delayed-type hypersensitivity to heparin with tolerance of its intravenous administration.
    Irion R; Gall H; Peter RU
    Contact Dermatitis; 2000 Oct; 43(4):249-50. PubMed ID: 11011948
    [No Abstract]   [Full Text] [Related]  

  • 25. [Successful treatment with fondaparinux in heparin-induced thrombocytopenia and thrombosis].
    Seculini Patiño CE; Pascualini MF; Tabares AH
    Medicina (B Aires); 2015; 75(5):307-10. PubMed ID: 26502466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances and contemporary issues in prophylaxis for deep vein thrombosis.
    Hirsh J
    Chest; 2003 Dec; 124(6 Suppl):347S-348S. PubMed ID: 14668416
    [No Abstract]   [Full Text] [Related]  

  • 27. Application, tolerance and safety of fondaparinux therapy in a German hospital: a prospective single-centre experience.
    Schindewolf M; Scheuermann J; Kroll H; Marzi I; Kaufmann R; Boehncke WH; Ludwig RJ; Lindhoff-Last E
    Thromb Res; 2012 Jan; 129(1):17-21. PubMed ID: 21741076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fondaparinux cross-reacts with heparin antibodies in vitro in a patient with fondaparinux-related thrombocytopenia.
    Pistulli R; Oberle V; Figulla HR; Yilmaz A; Pfeifer R
    Blood Coagul Fibrinolysis; 2011 Jan; 22(1):76-8. PubMed ID: 21076279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience.
    Grouzi E; Kyriakou E; Panagou I; Spiliotopoulou I
    Clin Appl Thromb Hemost; 2010 Dec; 16(6):663-7. PubMed ID: 19825921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fondaparinux therapy in a hemodialysis patient with heparin-induced thrombocytopenia type II.
    Wellborn-Kim JJ; Mitchell GA; Terneus WF; Stowe CL; Malias MA; Sparkman GM; Hanson GW
    Am J Health Syst Pharm; 2010 Jul; 67(13):1075-9. PubMed ID: 20554593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of heparin-induced thrombocytopenia with fondaparinux.
    Harenberg J; Jörg I; Fenyvesi T
    Haematologica; 2004 Aug; 89(8):1017-8. PubMed ID: 15339691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-immediate heparin and heparinoid cutaneous allergic reactions: a role for fondaparinux.
    Tan E; Thompson G; Ekstrom C; Lucas M
    Intern Med J; 2018 Jan; 48(1):73-77. PubMed ID: 29314514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of platelet monitoring in patients receiving thromboprophylaxis with fondaparinux or a low molecular weight heparin. The Ariane study].
    Gouin-Thibault I; Liard F; Van-Ganse E; Vespa L; Gaudin AF; Nachit-Ouinekh F
    Presse Med; 2011 Sep; 40(9 Pt 1):e365-75. PubMed ID: 21515025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dabigatran offers the simplest solution for thromboprophylaxis after orthopaedic surgery in patients allergic to low-molecular-weight heparins.
    Garcia-Ortega P; Asencio J
    Br J Haematol; 2010 Oct; 151(1):84-5. PubMed ID: 20618326
    [No Abstract]   [Full Text] [Related]  

  • 36. Chronic fondaparinux use in a hemodialysis patient with heparin-induced thrombocytopenia type II and extracorporeal circuit thrombosis-a case report and review of the literature.
    Brown P; Jay R; Fox A; Oliver M
    Hemodial Int; 2013 Jul; 17(3):444-9. PubMed ID: 23216938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimising the risk of heparin-induced osteoporosis during pregnancy.
    Hawkins D; Evans J
    Expert Opin Drug Saf; 2005 May; 4(3):583-90. PubMed ID: 15934862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery.
    Bergqvist D
    Vasc Health Risk Manag; 2006; 2(4):365-70. PubMed ID: 17323590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. Tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux.
    Koch P
    Contact Dermatitis; 2003 Dec; 49(6):276-80. PubMed ID: 15025697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
    Welzel D; Hull R; Fareed J
    Int Angiol; 2011 Jun; 30(3):199-211. PubMed ID: 21617603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.